Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract

A protein and airway technology, applied in respiratory diseases, peptide/protein components, medical preparations containing active ingredients, etc., can solve the problem of reduced activity of fibrinolysis

Inactive Publication Date: 2008-09-10
DRUGRECURE
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At the same time, local fibrinolysis was significantly inhibited, i.e., coagulation was locally upregulated and fibrinolytic activity was significantly reduced in the injured lung

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0141] A 60-year-old patient with severe ARDS had opacities mainly concentrated in the right lung as judged by thoracic radiography. Bronchoalveolar lavage (BAL) was performed via bronchoscope in the right lower lobe bronchi using a single dose of 5 mg of activated drotrecogin-α (Xigris) dissolved in 20 ml of normal saline. No significant side effects and airway bleeding were observed. The next day, the cloudiness cleared to some extent in the right lower lobe treated with BAL. On the other hand, as PaO 2 / FiO 2 A single dose of APC did not improve gas exchange as monitored by the ratio.

Embodiment 2

[0143] An 11-year-old boy with Mb Hodgkin's lymphoma (Mb. Hodgkin) was first treated with chemotherapy in 2003. A recurrence was recorded in 2005, at which time he was treated with radiation therapy and autologous bone marrow transplantation (BMT). A lung biopsy performed prior to ICU admission showed no evidence of graft-versus-host disease (GvHD) in the lungs. There were no signs of lymphomatous infiltration. Nine days after BMT, he was admitted to the ICU with acute pulmonary insufficiency (ALI) and persistent high fever with sepsis. Treat with broad-spectrum empiric antibiotics first. On day 4, oxygen capacity was further reduced, despite high PEEP, PaO 2 / FiO 2 The ratio is still ) started inhalation therapy with activated protein C (activated Drotrecogin-α) at ​​a dose of 5 mg×3. After 3 doses 12 hours later, infiltrates on chest radiographs were significantly reduced; concomitantly, arterial oxygen saturation increased from 85% to 95%, while FiO 2 = 1.0. There w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and / or reducing unwanted effects associated with systemic administration of natural anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of natural anticoagulants or biologically active derivatives thereof.

Description

[0001] All patent and non-patent literature cited in the application or in the present application are also incorporated herein by reference in their entirety. field of invention [0002] The present invention provides methods of preventing acute, recurrent and chronic fibrin deposition in the spaces of the airways (particularly alveoli and / or bronchioles) in children and adults in any disease associated with fibrin deposition. These conditions include: inflammatory lung diseases (such as acute lung injury (ALI)), which can be associated with direct or indirect lung trauma, for example, after ventilator therapy (ventilator-induced lung injury (ventilator Induced Lung Injury, VILI)); inflammatory conditions, such as autoimmune diseases, pancreatitis, aspiration pneumonia; inhalation of toxic fumes; acute respiratory distress syndrome (ARDS), which is a more serious manifestation of acute lung injury; infection, Such as sepsis, severe sepsis, and septic shock; pneumonia of any c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/48A61P11/00
CPCA61K9/007A61K9/0075A61K38/57A61K38/48A61K9/0078A61K38/4866A61P1/18A61P11/00A61P11/06A61P11/16A61P29/00A61P31/04A61P43/00A61P7/02A61K38/16A61K38/00
Inventor 拉斯·O·厄滕塔尔
Owner DRUGRECURE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com